160 related articles for article (PubMed ID: 22149905)
1. Effect of intravitreal bevacizumab (Avastin(®)) therapy in malignant hypertensive retinopathy: a report of two cases.
Kim EY; Lew HM; Song JH
J Ocul Pharmacol Ther; 2012 Jun; 28(3):318-22. PubMed ID: 22149905
[TBL] [Abstract][Full Text] [Related]
2. Tremendous result of bevacizumab in malignant hypertensive retinopathy.
Al-Halafi AM
Oman J Ophthalmol; 2015; 8(1):61-3. PubMed ID: 25709280
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
9. Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema.
Forte R; Cennamo G; Breve MA; Vecchio EC; de Crecchio G
J Ocul Pharmacol Ther; 2012 Feb; 28(1):69-75. PubMed ID: 22059904
[TBL] [Abstract][Full Text] [Related]
10. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
14. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab intravitreal injections in the treatment of diabetic macular oedema.
Małgorzata W; Diana D; Agnieszka B; Zofia M
Klin Oczna; 2013; 115(1):15-9. PubMed ID: 23882733
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
[TBL] [Abstract][Full Text] [Related]
19. Treatment of macular edema because of occlusive vasculitis with bevacizumab (avastin): efficacy of three consecutive monthly injections.
Nuti E; Traversi C; Marigliani D; Balestrazzi A; Alegente M; Martone G; Malandrini A; Romeo N; Mazzotta C; Tosi GM
Retina; 2011 Oct; 31(9):1863-70. PubMed ID: 21799465
[TBL] [Abstract][Full Text] [Related]
20. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
Bakri SJ; Larson TA
Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
